U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. Semaglutide is a once-daily glucagon-like peptide-1 analog that differs to others by the presence of an acyl group with a steric diacid at Lys26 and a large synthetic spacer and modified by the presence of a α-aminobutyric acid in position 8 which gives stability against the dipeptidylpeptidase-4. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OZEMPIC

Approved Use

OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Launch Date

1.51234557E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.5 nM
0.5 mg single, subcutaneous
dose: 0.5 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SEMAGLUTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9.7 nM
0.5 mg single, subcutaneous
dose: 0.5 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SEMAGLUTIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3026 nM × h
0.5 mg single, subcutaneous
dose: 0.5 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SEMAGLUTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3080 nM × h
0.5 mg single, subcutaneous
dose: 0.5 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SEMAGLUTIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
150 h
0.5 mg single, subcutaneous
dose: 0.5 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SEMAGLUTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
151 h
0.5 mg single, subcutaneous
dose: 0.5 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SEMAGLUTIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
unknown, unknown
SEMAGLUTIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 ug/kg 1 times / day single, subcutaneous
Highest studied dose
Dose: 20 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 20 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea
Vomiting
Dyspepsia
Headache
Decreased appetite
Sources:
15 ug/kg 1 times / day single, subcutaneous
MTD
Dose: 15 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 15 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea
Vomiting
Dyspepsia
Headache
Decreased appetite
Sources:
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (2.9%)
Vomiting (1.7%)
Diarrhea (0.9%)
Abdominal pain (0.6%)
Abdominal pain upper (0.5%)
Abdominal discomfort (0.4%)
Dyspepsia (0.3%)
Constipation (0.3%)
Abdominal distension (0.3%)
Gastritis (0.2%)
GERD (0.2%)
Pancreatitis acute (0.2%)
Decreased appetite (0.7%)
Weight decreased (0.3%)
Lipase increased (0.2%)
Asthenia (0.2%)
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
20 mg 1 times / day single, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: single
Dose: 20 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(600 mg; single)
Sources:
healthy, mean age 34.8 years
n = 10
Health Status: healthy
Age Group: mean age 34.8 years
Sex: M
Population Size: 10
Sources:
1.5 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.5 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.5 mg, 1 times / week
Sources:
healthy, mean age 37.7 years
n = 83
Health Status: healthy
Age Group: mean age 37.7 years
Sex: M+F
Population Size: 83
Sources:
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Disc. AE: Lipase increased, Decreased appetite...
Other AEs: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Lipase increased (12.5%)
Decreased appetite (6.25%)
Nausea (6.25%)
Vomiting (3.1%)
Other AEs:
Nausea (46.9%)
Vomiting (40.6%)
Eructation (43.8%)
Abdominal pain (28.1%)
Diarrhoea (12.5%)
Abdominal distension (21.9%)
Dyspepsia (31.3%)
Abdominal discomfort (15.6%)
Flatulence (12.5%)
Abdominal pain upper (9.4%)
Infrequent bowel movements (9.4%)
Toothache (12.5%)
Decreased appetite (78.1%)
Nasopharyngitis (31.3%)
Headache (37.5%)
Fatigue (25%)
Asthenia (9.4%)
Lipase increased (21.9%)
Sources:
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Disc. AE: Lipase increased, Vomiting...
Other AEs: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Lipase increased (9.1%)
Vomiting (9.1%)
Aortic aneurysm (9.1%)
Other AEs:
Nausea (54.5%)
Vomiting (45.5%)
Eructation (27.3%)
Diarrhoea (18.2%)
Abdominal distension (9.1%)
Dyspepsia (36.4%)
Abdominal discomfort (27.3%)
Flatulence (9.1%)
Abdominal pain upper (9.1%)
Decreased appetite (90.9%)
Nasopharyngitis (18.2%)
Headache (36.4%)
Fatigue (18.2%)
Sources:
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Disc. AE: Gastrointestinal disorder (NOS)...
Other AEs: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS)
Other AEs:
Nausea (57.4%)
Vomiting (27.7%)
Diarrhea (23.4%)
Dyspepsia (12.8%)
Constipation (6.4%)
Nasopharyngitis (6.4%)
Gastroenteritis (4.3%)
Urinary tract infection (4.3%)
Fatigue (12.8%)
Asthenia (10.6%)
Anorexia (31.9%)
Decreased appetite (17%)
Musculoskeletal and connective tissue disorders (8.5%)
Hypertension (2.1%)
Injury, poisoning and procedural complications (8.5%)
Skin and subcutaneous tissue disorders (2.1%)
Respiratory, thoracic and mediastinal disorders (2.1%)
Cardiac disorders (2.1%)
Psychiatric disorders (2.1%)
Sources:
1 mg 1 times / week multiple, subcutaneous
Recommended
Dose: 1 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, mean age 59.5 years
n = 289
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 59.5 years
Sex: M+F
Population Size: 289
Sources:
Disc. AE: Nausea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Sources:
unknown
Other AEs: Thyroid tumor...
AEs

AEs

AESignificanceDosePopulation
Decreased appetite
20 ug/kg 1 times / day single, subcutaneous
Highest studied dose
Dose: 20 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 20 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Dyspepsia
20 ug/kg 1 times / day single, subcutaneous
Highest studied dose
Dose: 20 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 20 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Headache
20 ug/kg 1 times / day single, subcutaneous
Highest studied dose
Dose: 20 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 20 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Nausea
20 ug/kg 1 times / day single, subcutaneous
Highest studied dose
Dose: 20 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 20 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Vomiting
20 ug/kg 1 times / day single, subcutaneous
Highest studied dose
Dose: 20 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 20 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Decreased appetite
15 ug/kg 1 times / day single, subcutaneous
MTD
Dose: 15 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 15 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Dyspepsia
15 ug/kg 1 times / day single, subcutaneous
MTD
Dose: 15 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 15 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Headache
15 ug/kg 1 times / day single, subcutaneous
MTD
Dose: 15 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 15 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Nausea
15 ug/kg 1 times / day single, subcutaneous
MTD
Dose: 15 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 15 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Vomiting
15 ug/kg 1 times / day single, subcutaneous
MTD
Dose: 15 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 15 ug/kg, 1 times / day
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
Asthenia 0.2%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
GERD 0.2%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Gastritis 0.2%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Lipase increased 0.2%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Pancreatitis acute 0.2%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Abdominal distension 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Constipation 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Dyspepsia 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Weight decreased 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Abdominal discomfort 0.4%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Abdominal pain upper 0.5%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Abdominal pain 0.6%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Decreased appetite 0.7%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Diarrhea 0.9%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Vomiting 1.7%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Nausea 2.9%
Disc. AE
8 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
unhealthy, adult
n = 4379
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: adult
Sex: M+F
Population Size: 4379
Sources: Page: 213051Orig1s000MedR.pdf -p.153, p.175
Diarrhoea 12.5%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Flatulence 12.5%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Toothache 12.5%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Lipase increased 12.5%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Abdominal discomfort 15.6%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Abdominal distension 21.9%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Lipase increased 21.9%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Fatigue 25%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Abdominal pain 28.1%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Vomiting 3.1%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Dyspepsia 31.3%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Nasopharyngitis 31.3%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Headache 37.5%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Vomiting 40.6%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Eructation 43.8%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Nausea 46.9%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Decreased appetite 6.25%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Nausea 6.25%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Decreased appetite 78.1%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Abdominal pain upper 9.4%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Asthenia 9.4%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Infrequent bowel movements 9.4%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
healthy, mean age 40.8 years
n = 32
Health Status: healthy
Age Group: mean age 40.8 years
Sex: M
Population Size: 32
Sources:
Diarrhoea 18.2%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Fatigue 18.2%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Nasopharyngitis 18.2%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Abdominal discomfort 27.3%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Eructation 27.3%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Dyspepsia 36.4%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Headache 36.4%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Vomiting 45.5%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Nausea 54.5%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Abdominal distension 9.1%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Abdominal pain upper 9.1%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Flatulence 9.1%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Aortic aneurysm 9.1%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Lipase increased 9.1%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Vomiting 9.1%
Disc. AE
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Decreased appetite 90.9%
40 mg 1 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Co-administed with::
sodium N-(8-[2-hydroxybenzoyl]amino) caprylate(300 mg; 10 weeks)
Sources:
unhealthy, mean age 55.3 years
n = 11
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 55.3 years
Sex: M
Population Size: 11
Sources:
Asthenia 10.6%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Dyspepsia 12.8%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Fatigue 12.8%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Decreased appetite 17%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Cardiac disorders 2.1%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Hypertension 2.1%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Psychiatric disorders 2.1%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Respiratory, thoracic and mediastinal disorders 2.1%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Skin and subcutaneous tissue disorders 2.1%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Diarrhea 23.4%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Vomiting 27.7%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Anorexia 31.9%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Gastroenteritis 4.3%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Urinary tract infection 4.3%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Nausea 57.4%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Constipation 6.4%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Nasopharyngitis 6.4%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Injury, poisoning and procedural complications 8.5%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Musculoskeletal and connective tissue disorders 8.5%
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Gastrointestinal disorder (NOS) Disc. AE
1.6 mg 1 times / week multiple, subcutaneous
Highest studied dose
Dose: 1.6 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1.6 mg, 1 times / week
Sources:
unhealthy, mean age 56.4 years
n = 47
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 56.4 years
Sex: M+F
Population Size: 47
Sources:
Abdominal pain Disc. AE
1 mg 1 times / week multiple, subcutaneous
Recommended
Dose: 1 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, mean age 59.5 years
n = 289
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 59.5 years
Sex: M+F
Population Size: 289
Sources:
Constipation Disc. AE
1 mg 1 times / week multiple, subcutaneous
Recommended
Dose: 1 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, mean age 59.5 years
n = 289
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 59.5 years
Sex: M+F
Population Size: 289
Sources:
Diarrhea Disc. AE
1 mg 1 times / week multiple, subcutaneous
Recommended
Dose: 1 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, mean age 59.5 years
n = 289
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 59.5 years
Sex: M+F
Population Size: 289
Sources:
Nausea Disc. AE
1 mg 1 times / week multiple, subcutaneous
Recommended
Dose: 1 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, mean age 59.5 years
n = 289
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 59.5 years
Sex: M+F
Population Size: 289
Sources:
Vomiting Disc. AE
1 mg 1 times / week multiple, subcutaneous
Recommended
Dose: 1 mg, 1 times / week
Route: subcutaneous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, mean age 59.5 years
n = 289
Health Status: unhealthy
Condition: Type 2 diabetes
Age Group: mean age 59.5 years
Sex: M+F
Population Size: 289
Sources:
Thyroid tumor
unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes [IC50 2.95 uM]
yes [IC50 3.5 uM]
yes [IC50 >40 uM]
yes [IC50 >5 uM]
yes [IC50 >5 uM]
yes [IC50 >5 uM]
yes [IC50 >5 uM]
yes [IC50 >5 uM]
yes [IC50 >5 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Semaglutide seems to be more effective the other GLP-1Ras.
2017 Dec
Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?
2017 Dec
Patents

Sample Use Guides

Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly (2.1).  Administer once weekly at any time of day, with or without meals (2.1).  If a dose is missed administer within 5 days of missed dose (2.1).  Inject subcutaneously in the abdomen, thigh, or upper arm (2.2).
Route of Administration: Other
Semaglutide displaced [125I]-GLP1 from human GLP1 receptor expressed in BHK cells after 2 hrs in absence of human serum albumin with the IC50 value of 0.38 nM.
Substance Class Protein
Created
by admin
on Fri Jun 25 21:23:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:23:15 UTC 2021
Protein Type PEPTIDE
Protein Sub Type
Sequence Type COMPLETE
Record UNII
53AXN4NNHX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SEMAGLUTIDE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
NN-9535
Code English
SEMAGLUTIDE [INN]
Common Name English
SEMAGLUTIDE [WHO-DD]
Common Name English
SEMAGLUTIDE [ORANGE BOOK]
Common Name English
NN9535
Code English
NNC-0113-0217
Code English
SEMAGLUTIDE [MI]
Common Name English
SEMAGLUTIDE [JAN]
Common Name English
OZEMPIC
Brand Name English
WEGOVY
Brand Name English
NNC 0113-0217
Code English
SEMAGLUTIDE [USAN]
Common Name English
RYBELSUS
Brand Name English
Classification Tree Code System Code
WHO-ATC A10BJ06
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
NCI_THESAURUS C98085
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
NDF-RT N0000178480
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
Code System Code Type Description
MERCK INDEX
M12052
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
PUBCHEM
56843331
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
CAS
910463-68-2
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
RXCUI
1991302
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
DRUG CENTRAL
5267
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL2108724
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
LACTMED
Semaglutide
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
FDA UNII
53AXN4NNHX
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
DRUG BANK
DB13928
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
EVMPD
SUB32188
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
INN
9113
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
WIKIPEDIA
Semaglutide
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
NCI_THESAURUS
C152328
Created by admin on Fri Jun 25 21:23:15 UTC 2021 , Edited by admin on Fri Jun 25 21:23:15 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL